Nasdaq GlobeNewswire

Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares


GAITHERSBURG, Md., 2016-02-05 21:00 CET (GLOBE NEWSWIRE) --

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, in connection with Novavax’ previously announced initial offering of 3.75% Senior Convertible Notes due 2023 (the “Notes”), the initial purchasers have exercised in part their previously announced over-allotment option to purchase an additional $25 million aggregate principal amount of the Notes (the “Additional Notes”). The closing of the sale of the Additional Notes occurred on February 5, 2016. Following the closing of the Additional Notes, Novavax has issued a total of $325 million aggregate principal amount of its 3.75% Senior Convertible Notes due 2023. Following today’s closing, the initial purchasers retain the option, expiring February 24, 2016, to purchase up to an additional $5 million aggregate principal amount of the Notes on the same terms and conditions as previously disclosed. The Notes were offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Citigroup and J.P. Morgan acted as joint book-running managers of the offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.

Assuming the initial purchasers do not exercise the remainder of their over-allotment option, Novavax will have received aggregate net proceeds from the offering (including the previously-announced net proceeds of approximately $291 million from the initial closing on January 29, 2016) of approximately $315 million, after deducting the initial purchasers’ discounts and commissions, but prior to deducting estimated offering expenses. Novavax used approximately $2.9 million of the net proceeds from the offering of the Additional Notes to pay the cost of additional capped call transactions entered into in connection with the partial exercise of the over-allotment option. The cap price of the capped call transactions will be $9.73 per share, which represents a premium of approximately 75% based on the last reported sale price of Novavax’ common stock of $5.56 per share on the day of pricing of the Notes, January 25, 2016, and is subject to certain adjustments under the terms of the additional capped call transactions.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Forward-Looking Statements 
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, potential exercise by the initial purchasers of their remaining over-allotment option and the possible effects of the capped call transactions. Each forward‐looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to, those related to the conduct, timing and potential results from Novavax’ clinical-trials and other preclinical studies, Novavax’ plans for and potential timing of regulatory filings, the expected timing and content of regulatory actions, Novavax’ plans regarding partnering activities and business development initiatives, and the timing and success of Novavax’ commercialization, if any, of its product candidates. In addition, Novavax’ management retains broad discretion with respect to the allocation of the net proceeds of this offering. Applicable risks also include those that are listed under the heading “Risk Factors” and elsewhere in Novavax’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014, in addition to the risk factors that are included from time to time in Novavax’ subsequent SEC filings. Novavax undertakes no obligation to update these forward-looking statements to reflect events or circumstances occurring after this press release. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release. All forward‐looking statements are qualified in their entirety by this cautionary statement.

         Novavax, Inc.
         Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Andrea N. Flynn, Ph.D.
         Senior Manager, Investor Relations

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Orion Biotechnology Canada Announces Closing of $5 Million Financing20.3.2018 22:03Pressemelding

OTTAWA, March 20, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd today announced it has completed a US$5 million private placement financing late last year. "We are delighted to have secured the financial resources during this period of rapid expansion," said Mark Groper, President and Chief Executive Officer. "This financing allows Orion, as a private company, to continue development of its expanding pipeline of innovative products, including expansion of our infrastructure and human resources. It also provides external validation of the unique value proposition of the company's pipeline products which include candidates in the areas of Sexual Health, Oncology and Multiple Sclerosis. Orion is a research and development organization committed to developing novel approaches to address serious health issues. A prime example of this is the company's microbicide candidate, OB-001, which is being evaluated as a contraceptive gel which also prevents the transmission of HIV. "This is

Meltwater acquires privacy-by-design social data platform DataSift to strengthen its AI-driven analytics offering20.3.2018 18:45Pressemelding

SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Meltwater, a pioneer of media intelligence and now Outside Insight, today announced its acquisition of DataSift, a privacy-by-design data and analytics platform that extracts real-time insights from social and online data sources, while protecting user privacy. This acquisition, Meltwater's sixth in the last year, solidifies the company's emergence as a leading provider of AI-powered competitive intelligence through its Outside Insight platform. "By combining advances in machine learning and the vast amount of publicly available information on the internet, you can today understand and track Porter's Five Forces in real time to understand strategic opportunities and threats for your business. Executives that take advantage of this new opportunity create an unfair information advantage over those who don't," explained Jorn Lyseggen, CEO and founder of Meltwater. "DataSift has built a scalable platform that lets developers build data scie

VITEC Adds Powerful New Video Wall and DRM Functionality to EZ TV IPTV and Digital Signage Platform20.3.2018 17:00Pressemelding

SUNNYVALE, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that its award-winning, enterprise-grade EZ TV IPTV and Digital Signage Platform can now manage and drive complex video wall setups and is interoperable with the latest content protection and DRM standards required by the leading services providers for IPTV deployments. These capabilities are fully supported through the EZ TV Platform, with DRM integration also available across VITEC's IPTV set-top-boxes, signage end-points, and the cutting-edge EZ TV IPTV mobile app. Attendees will see a live demonstration of the new EZ TV release at the 2018 NAB Show, April 9-12, at the Las Vegas Convention Center - booth SL6821. VITEC's video wall solution is designed to simplify deployment and management of projects involving IPTV, digital signage, and video wall content, while delivering a breathtaking visual experience. The new EZ TV video wall proces

Librestream Powers New Remote Assistance Service from Safran Helicopter Engines20.3.2018 16:00Pressemelding

WINNIPEG, Manitoba, March 20, 2018 (GLOBE NEWSWIRE) -- Librestream is pleased to announce that Safran Helicopter Engines has successfully deployed a remote video technical assistance service using the Onsight collaborative platform. Safran Helicopter Engines first announced this innovative Expert link branded service at the HAI Heli-Expo February 28 in conjunction with Heli Austria, Rotortech Services Inc and Heligo, first customers of this new service. Using the Expert link service, helicopter operators can connect immediately with remote experts at Safran Helicopter Engines to assist with technical diagnostics and maintenance tasks. The service includes a secure live video feed that remotely brings the eyes and ears of Safran experts into customer facilities to mentor and share maintenance best practices. "We felt that Expert link was an important part of our digital service strategy, which also includes services such as our EngineLife® Customer Portal and Health Monitoring solutions

SD-WAN Market Report Names Aryaka Top Independent Pure Play SD-WAN Market Leader Again in CY Q4 201720.3.2018 14:53Pressemelding

IHS Markit Report illustrates SD-WAN market is a two-horse race between Aryaka and VMware, showcases Aryaka's significant lead over Cisco, Riverbed, Silver-Peak, and others SAN MATEO, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Aryaka® maintained its position as the largest independent pure play SD-WAN provider by market share and revenues, and continued its march to close the gap on VMware in Q4 2017, according to the latest industry report from IHS Markit. The "IHS Markit's Data Center Network Equipment Quarterly Market Tracker" says Aryaka garnered 17% share of the SD-WAN market in Q4 2017, once again securing the company's lead over legacy networking vendors like Cisco and Riverbed. Aryaka's market share is listed as only 2% less than VMware's. "[Aryaka's] Customer deployments continue to focus on the replacement of MPLS with several large wins in the US, a large service provider partner in Asia Pacific, and a large service provider partner in EMEA serving the automotive sector," Cl

NRT Acquires OfferCraft, Award-Winning Provider of Artificial Intelligence, Gamification and Digital Content Solutions20.3.2018 14:22Pressemelding

Acquisition of hyper-engagement platform enhances NRT's ability to deliver transformative, revenue-generating technology to its customers LAS VEGAS, March 20, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT"), a leading provider of digital commerce experiences in gaming and financial services, announced that it has acquired the assets of privately held OfferCraft, a software company that uses artificial intelligence and gamification to drive loyalty, engagement and revenue. Terms of the agreement are not disclosed. The deal will allow NRT to integrate OfferCraft's patent-pending solutions into its existing kiosk, mobile, table games and cashless payment product lines, while also expanding into entirely new areas across nearly every digital channel. OfferCraft's artificial intelligence software allows offers, coupons and rewards to be distributed digitally across email, SMS, websites, social media, kiosks, the Point of Sale, signage, and more. Unlike traditional marketing content, t

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom